UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients

PloS one, 2014-02, Vol.9 (2), p.e87974

2014

Volltextzugriff (PDF)

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

Journal of hepatology, 2011-06, Vol.54 (6), p.1114-1122

2011

Volltextzugriff (PDF)

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection

Journal of hepatology, 2008-11, Vol.49 (5), p.688-694

2008

Volltextzugriff (PDF)

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

Gastroenterology (New York, N.Y. 1943), 2011-11, Vol.141 (5), p.1656-1664

2011

Volltextzugriff (PDF)

Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues

Hepatology (Baltimore, Md.), 2010-01, Vol.51 (1), p.73-80

2010

Volltextzugriff (PDF)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2143-2154

2013

Volltextzugriff (PDF)

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

The lancet. Gastroenterology & hepatology, 2018-10, Vol.3 (10), p.671-680

2018

Volltextzugriff (PDF)

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2155-2163

2013

Volltextzugriff (PDF)

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study

Journal of Crohn's and colitis, 2018-11, Vol.12 (10), p.1170-1179

2018

Volltextzugriff (PDF)

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients

The Journal of pharmacology and experimental therapeutics, 2014-11, Vol.351 (2), p.403-412

2014

Volltextzugriff (PDF)

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.698-705

2014

Volltextzugriff (PDF)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

PloS one, 2015-12, Vol.10 (12), p.e0144004

2015

Volltextzugriff (PDF)

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

Antiviral therapy, 2013-01, Vol.18 (8), p.1015-1019

2013

Volltextzugriff (PDF)

All-trans retinoic acid for treatment of chronic hepatitis C

Liver international, 2008-03, Vol.28 (3), p.347-354

2008

Volltextzugriff (PDF)

No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial

Digestive and liver disease, 2013-04, Vol.45 (4), p.323-329

2013

Volltextzugriff (PDF)

Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

Transplant international, 2007-07, Vol.20 (7), p.583-590

2007

Volltextzugriff (PDF)

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection

Journal of hepatology, 2008-11, Vol.49 (5), p.688

2008

Volltextzugriff (PDF)

Clinical Studies: Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon- alpha therapy

Liver international, 2006-04, Vol.26 (3), p.319-325

2006

Volltextzugriff (PDF)

1012 Consensus interferon and ribavirin retreatment of chronic HCV patients with non-response or relapse after previous alpha-interferon therapy

Hepatology (Baltimore, Md.), 2003, Vol.38, p.644-644

2003

Volltextzugriff (PDF)

The Trimera Mouse Model of HBV and HCV Infection

Models of Viral Hepatitis, 2005, Vol.25, p.146-160

2005

Volltextzugriff (PDF)

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

The New England journal of medicine, 2013-08, Vol.369 (7), p.630-639

2013

Volltextzugriff (PDF)

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?

The American journal of gastroenterology, 2008-12, Vol.103 (12), p.3063-3070

2008

Volltextzugriff (PDF)

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

Gastroenterology (New York, N.Y. 1943), 2011-12, Vol.141 (6), p.2047-2055

2011

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)
Buchkapitel
(1)

Sprache

Englisch
(34)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Humans
(26)
Life Sciences & Biomedicine
(26)
Female
(18)
Male
(18)
Adult
(16)
Middle Aged
(16)
Gastroenterology & Hepatology
(15)
Antiviral Agents - Therapeutic Use
(12)
Hepacivirus - Genetics
(12)
Hepatitis C, Chronic - Drug Therapy
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Antiviral Agents - Adverse Effects
(10)
Ribavirin - Therapeutic Use
(10)
Treatment Outcome
(10)
Ribavirin - Adverse Effects
(9)
Viral Hepatitis
(9)
Antiviral Agents
(8)
Drug Therapy, Combination
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

All-trans retinoic acid for treatment of chronic hepatitis C

No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection

Clinical Studies: Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon- alpha therapy

1012 Consensus interferon and ribavirin retreatment of chronic HCV patients with non-response or relapse after previous alpha-interferon therapy

The Trimera Mouse Model of HBV and HCV Infection

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

Suchergebnisse filtern